Endocannabinoid-related molecules predict the metabolic efficacy of GLP-1 receptor agonism in humans with obesity
Observational studyHumans
- Design
- Observational study
- Subjects
- 43 people with obesity in weight loss maintenance: 23 treated with liraglutide and 20 without
- Dose used in the study
- Not applicable; palmitoylethanolamide was measured in plasma, not given
- Duration
- Samples before the study, after diet-induced weight loss, and after 52 weeks of treatment
- What was measured
- Plasma N-acylethanolamines (OEA, AEA, PEA) and whether baseline levels predicted liraglutide effects on fasting insulin and triglycerides.
What the authors reported
The study found:
- Liraglutide lowered plasma OEA but did not change AEA or PEA.
- High pre-treatment OEA predicted greater effects on fasting insulin and triglycerides.
- High pre-treatment PEA and AEA predicted greater effects on triglycerides.
Limits of this study
A small biomarker analysis of 43 people; it cannot show any effect of taking PEA. Funding and conflicts not stated in the abstract.
Source
PubMed 37924474 · doi:10.1007/s40618-023-02228-8
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.